These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22899400)

  • 21. RAS Mutation in Mucinous Carcinoma of the Ovary.
    Panyavaranant P; Teerapakpinyo C; Pohthipornthawat N; Oranratanaphan S; Shuangshoti S; Triratanachat S
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1127-1132. PubMed ID: 31030485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
    Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
    Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
    Kim EK; Kim KA; Lee CY; Shim HS
    PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
    Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
    J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.
    Jia W; Chang B; Sun L; Zhu H; Pang L; Tao L; Zou H; Du J; Dong Y; Qi Y; Jiang J; Liang W; Li F; Zhao X
    Int J Clin Exp Pathol; 2014; 7(9):5940-9. PubMed ID: 25337238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
    Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
    Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
    Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade.
    Davison JM; Choudry HA; Pingpank JF; Ahrendt SA; Holtzman MP; Zureikat AH; Zeh HJ; Ramalingam L; Zhu B; Nikiforova M; Bartlett DL; Pai RK
    Mod Pathol; 2014 Nov; 27(11):1521-39. PubMed ID: 24633196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients.
    Chao WR; Lee YJ; Lee MY; Sheu GT; Han CP
    Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1072-1077. PubMed ID: 34794740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.
    Kim SK; Cho NH
    Int J Clin Exp Pathol; 2014; 7(7):4222-30. PubMed ID: 25120802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
    Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
    Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
    Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH
    Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
    Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.
    Chao WR; Lee MY; Lin WL; Chen CK; Lin JC; Koo CL; Sheu GT; Han CP
    Hum Pathol; 2014 Apr; 45(4):810-6. PubMed ID: 24656091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients.
    Vlajnic T; Andreozzi MC; Schneider S; Tornillo L; Karamitopoulou E; Lugli A; Ruiz C; Zlobec I; Terracciano L
    Mod Pathol; 2011 Oct; 24(10):1404-12. PubMed ID: 21743435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.